Background Insulin-like growth factor 1 receptor (IGF1R) represents a novel molecular target in non-smallcell-lung cancer (NSCLC). IGF1R and epidermal growth factor receptor (EGFR) activation are essential to mediate tumor cell survival, proliferation, and invasion. This study investigates the prognostic role of IGF1R and EGFR in surgically resected NSCLC. 
IGF1R gene located on chromosome 15q25-q26, which promotes oncogenic transformation, growth, and survival of cancer cells [3] [4] [5] [6] . The binding of IGF-I and IGF-II to the extracellular subunity domain of IGF1R activates the tyrosine kinase activity of IGF1R and triggers a cascade of reactions involving signal transduction pathways: the Ras, Raf, mitogen-activated protein kinase, and the phosphoinositol-3-kinase (PI3K)/AKT/BAD (Bcl-xL/Bcl2-associated death promoter) [7] . Currently several IGF1R inhibitors are undergoing clinical evaluation, including blocking antibodies and tyrosine kinase blockers. Phase I/II studies of these compounds indicated favorable toxicity profiles and promising activity [8] [9] [10] [11] . However, phase III trials of anti-IGF1R agent in NSCLC were recently discontinued owing to futility. These results stress the need to identify patient subpopulations that may preferentially benefit from anti-IGF1R therapy.
Several lines of evidence suggest an association between epidermal growth factor receptor (EGFR) and IGF1R pathways. Results of preclinical studies indicate that both receptors may heterodimerize [12] , are capable of transphosphorylation [13] , and share the same adaptor proteins and downstream signaling pathways [14] . Data on cell lines suggest that IGF1R mediates resistance to anti-EGFR therapy through continued activation of the PI3K-Akt pathway [15, 16] . Numerous ongoing clinical trials explore the efficacy of combination of EGFR and IGF1R inhibitors in patients with lung cancer.
The prognostic role of IGF1R has been previously investigated in human malignancies including NSCLC, leading to conflicting results. In breast cancer, IGF1R expression and activation have been linked to disease progression, increased resistance to radiotherapy, and poor prognosis [17, 18] . Fidler et al. [19] , in gefitinib-treated patients, showed counter-intuitive improved outcomes with the co-expression of IGF1R and EGFR in exploratory analyses. Cappuzzo et al. [20] observed that IGF1R expression was significantly associated with better survival in metastatic NSCLC patients treated with tyrosine kinase inhibitors (TKIs). The same authors, in another study [21] , showed that IGF1R expression did not represent a prognostic factor in resected NSCLC patients. Instead, Nakagawa et al. [22] observed that IGF1R expression was associated with reduced disease-free survival (DFS) in NSCLC. Recently, Dziadziuszko et al. [23] reported that IGF1R protein and gene expression did not associate with survival, whereas high IGF1R gene copy number harbored positive prognostic value. In a previous study, we showed that IGF1R and EGFR protein expression levels were associated, and high-level co-expression was a significant prognostic factor for worse DFS in early-stage NSCLC patients [24] . The conflicting available data and the growing interest on anti-IGF1R agents support the present study aimed to evaluate the relationship between IGF1R and EGFR gene copy number by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry (IHC), and to investigate the prognostic significance of these receptors in a cohort of patients with NSCLC who underwent pulmonary resection.
Materials and methods

Patients
Patients with a histological diagnosis of stage I-III NSCLC who had complete surgical resection of the primary tumor and were followed on a regular basis in a specified program were eligible for this study. Histological subtypes and grade of differentiation were determined according to the World Health Organization classification [25] . Patients were originally staged according to the 6th Edition of the IASLC TNM classification [26] . For this study, staging in all cases had been updated to reflect the 7th Edition [27] . Patients were classified as nonsmokers (never smoker), light smokers (\10 pack year and quit [10 years ago), and smokers. Neither chemotherapy nor radiotherapy had to be administered prior to surgery, and none of the patients had received EGFR target anticancer therapy during the followup period. Patients with disease recurrence or metastases were treated with platinum-based systemic chemotherapy. Follow-up including annual computed tomography (CT) scans of the chest and abdomen and chest X-rays in the 3-to 6-month intervals between the annual CT was planned for all patients in the first 3 years. Recurrences were detected by imaging techniques and when necessary confirmed by histological sampling.
The study was reviewed and approved by the institution's Ethics Committee, and the patients had to give their informed consent to surgical specimen analysis.
IGF1R and EGFR FISH analysis
Unstained 4 lm (?1 lm) sections of formalin-fixed paraffin-embedded (FFPE) tumor tissue were subjected to dual-color FISH assay using two probe sets: the laboratorydeveloped reagent IGF1R/CEP15 probe set combining the DNA insert encompassing IGF1R (BAC clone RP11 262P8) labeled with SpectrumRed d-UTPs and the SpectrumGreen CEP 15 probe and the commercial LSI EGFR Spectrum Orange/CEP7 Spectrum Green probe (Abbott Molecular). For both probe sets, assays were performed according to a previously described protocol [28] . Signals were enumerated in at least 100 tumor nuclei for each sample, using a fluorescence microscope (Zeiss AxioImager M1) equipped with single interference filters sets for green (FITC), red (Texas red), and blue (DAPI) as well as dual (red/green) and triple (blue, red, green) band pass filters. The copy number gain was evaluated utilizing a semi-quantitative grading system considering the increasing number of copies of the genes (disomy, low and high trisomy, low and high polysomy, and gene amplification) [29] . For documentation, images from representative fields were acquired by a charge-coupled device camera (CoolSnap, Photometrics) and merged using dedicated software (CytoVision, Genetix, San Jose CA).
IHC staining of IGF1R and EGFR
The IHC staining of IGF1R and EGFR was performed according to a previously described protocol [24] . IGF1R and EGFR protein expression were evaluated using mouse antibodies (clones 24-31, 1:50 diluted, Lab Vision Neomarkers, and clone 3147, 1:100 diluted, Zymed, Laboratories Inc., respectively). There are at present no validated scoring systems for interpreting IHC staining for IGF1R and EGFR, thus we applied previous description for EGFR [30] . A cutoff value of 10 % positive cells was used in order to avoid inclusion of scattered positivity of the same intensity found in the normal bronchial tissue. A specimen was considered IHC-positive (IHC?) only when a distinct cell membrane staining was evident (Fig. 1e, f) .
Statistical analysis
The v 2 -square or Fisher's exact test, where appropriate, was used to assess the association between clinical features and FISH analysis or the protein expression of biological factors. In a univariate exploratory analysis, maximum loglikelihood function was used to select the most discriminative cutoff values of IGF1R and EGFR FISH-positive (FISH?) for survival difference [31] . We found that the best discrimination was observed with a cutoff of C4.0 gene copies per cell displayed in 10 % of tumor cells to classify FISH?positive (FISH?) and FISH-negative (FISH-) patients. Overall survival (OS), disease-free survival (DFS), and the 95 % confidence intervals were evaluated by the Kaplan-Meier method comparing the different groups by log-rank test [32] . The Cox proportional hazards model was used to evaluate the prognostic role of each single studied parameter on OS and DFS, in univariate and multivariate analyses. Univariate survival analysis was conducted by exploring the interactions between the predictors, and the significant corrections were considered in the multivariate model (Cox, [33] ). OS was defined as the time from diagnosis to the date of death from any cause; patients who were not reported as having died at the time of the analysis were censored at the date they were last known to be alive. DFS was defined as the time from diagnosis to first local, regional or distant recurrence, second primary malignancy or death from any cause, whichever came first. Patients who were alive and did not experience recurrence at the time of the analysis were censored at the last disease assessment date. Unless otherwise specified, all tests are with one degree of freedom (df). A probability value of \0.05 was considered as statistically significant. Statistical analysis was performed using Matlab software (The MathWorks ver. 7.2.0.232).
Results
Patient characteristics
From April 2002 to February 2006, we collected tissue samples of 125 consecutive early stage radically resected NSCLC patients, who were referred to the Thoracic Surgery Unit, Perugia University Hospital, Italy. Table 1 summarizes the demographic and clinical data. were treated with chemotherapy, 9 (6.9 %) with radiotherapy, 4 (3.1 %) with chemo-radiotherapy, and the remaining 109 (87.7 %) received no adjuvant treatment.
At a median follow-up time of 48.9 months, 66 patients (52.8 %) had died: 64 (95.6 %) deaths were due to disease recurrence and two (4.4 %) to unrelated causes. Nine (15.2 %) of the 59 patients still on follow-up experienced recurrence. The median survival time was 61.4 months. Table 2 .
IGF1R and EGFR
IGF1R FISH? was associated with EGFR FISH? (p = 0.03). IGF1R and EGFR FISH? were associated with SCC histology (p = 0.01 and p = 0.04, respectively) as (Fig. 2) . A statistically significant difference in DFS was observed between patients with FISH? of both genes compared to other group (25 months vs not reached; HR 1.76; 95 % CI 0.99-3.13, p = 0.05, Fig. 2a (Table 4) . Only stage (II-III vs I) was an independent prognostic factor for OS (HR 2.57, 95 % CI 1.38-4.79, p = 0.003) (data not shown).
Discussion
In this study, we evaluated the prognostic role of two of the most relevant biomarkers in NSCLC, and to our knowledge, report for the first time that FISH ?/IHC? of both IGF1R/EGFR receptors represents a negative prognostic factor in radically resected NSCLC. There is an increasing interest on IGF1R in NSCLC. Identification of biomarkers for selecting patients most likely to derive clinical benefit from IGF1R inhibitors is needed. In vitro studies showed that expression of IGF1R correlates with sensitivity to IGF1R inhibitors, such as BMS-536924 [34] . Preclinical models showed that IGF1R expression could be implicated in acquired resistance to anti-EGFR strategies [13, 15] . In breast and prostate cancer cells, Jones et al. [13] showed that increased signaling via the IGF1R pathway leads to acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib. Chakravarti et al. [15] demonstrated that IGF1R can compensate for loss of EGFR function in primary glioma cell lines. Several new drugs, including mAbs and tyrosine kinase inhibitors, are currently under evaluation in patients with advanced NSCLC. Gualberto et al. [35] reported prolonged clinical benefit to figitumumab (F) in tumors with intense membrane localization of IGF1R. They also saw that high IGF1R in the chemotherapy alone group was associated with rapid disease progression. However, these results should be considered preliminary due to small cohort of patients (N = 45) investigated.
A phase II study randomly assigned 150 chemonaive NSCLC patients to the standard combination of carboplatin (C) plus paclitaxel (P) versus the same regimen plus CP-751,871, an anti-IGF1R mAb [11] . The study showed a significant improvement in response rate favoring the experimental arm, with an impressive 78 % response rate in patients with squamous histology.
The higher expression of the IGF1R protein in patients with squamous-cell carcinoma compared with non-squamous histology observed in the Karp's study, as well as in our study, provides the biological background for the highest sensitivity to anti-IGF1R agents observed in clinical trials in this patient population. A recent phase III trial of F administered in combination with CP failed to demonstrate survival benefit in advanced NSCLC patients [36] . EGFR epidermal growth factor receptor, IGF1R insulin-like growth factor receptor 1, FISH fluorescence in situ hybridization, IHC immunohistochemistry a IGF1R FISH-positive = copy number gain (CNG), C4 gene copies in C10 % of tumor cells
The study showed that the use of F with CP would be unlikely to improve overall survival compared to CP alone, mainly due to toxicity occurring in patients who randomly received F. However, in the subset of patients with high IGF serum levels, the addition of F appeared to offer benefit over CP. A second phase III trial investigating figitumumab with erlotinib versus erlotinib alone in the same population in the refractory setting (ADVIGO 1018; figitumumab plus erlotinib versus erlotinib in refractory advanced non-adenocarcinoma NSCLC) was also closed after an interim analysis in March 2010 because of the potential futility of the combination regimen. These results underscore the need to identify the patients most likely to benefit from anti-IGF1R therapy. The negative results in currently reported trials in unselected patients are disappointing, but they do not exclude the possibility that inhibition of the IGF-1R pathway could provide benefit in patients with specific molecular signatures. The preliminary results of presented trials suggest that high circulating levels of IGF-1 may be a potential, easy to test biomarker that may identify patients who may benefit from this class of agents.
A recent study has shown that the IGFIR and other molecules associated with the IGFIR pathway (e.g., IGF2R, IRS-1, -2) were overexpressed in NSCLC tumors undergoing epithelial-to-mesenchymal transition (EMT) [37] . The authors hypothesized that high circulating levels of free IGF-1(fIGF-1) could be associated with high IGF bioactivity in the tumor microenvironment, and this could favor EMT. Higher pre-treatment fIGF-1 levels were found to be predictive of the clinical benefit derived from the addition of Figitumumab to chemotherapy in NSCLC patients. In principle, the utilization of circulating factors as predictive biomarkers would appear to be more convenient than measurements requiring fresh or frozen neoplastic tissue. However, it should be noted that current assay methodologies, particularly those measuring IGF-1 bioactivity, are controversial, and it is necessary that assay methods be standardized [38] . In our study, IGF1R FISH? pattern was detected in 40 % of NSCLC cases and EGFR FISH? in 77 %, and there was a significant association between IGF1R and EGFR FISH? and histologic subtypes, with the highest gene copy number in squamous-cell carcinoma. These data are consistent with a recent report [23] . The pattern of expression and prognostic value of IGF1R expression in NSCLC remains controversial. Prior studies have shown that IGF1R expression is associated with longer survival in patients treated with gefitinib [19, 20] , poorer survival and higher expression in surgically treated lung adenocarcinomas versus squamous-cell carcinomas [39] or no association with survival in a similar population [40] and shorter DFS when co-expressed with EGFR in resected NSCLC [24] .
Our study, conducted in early NSCLC, using FISH and IHC methods to understand the relationship between the gene and its protein levels, showed that tumors with IGF1R/EGFR FISH?/IHC? were associated with a poorer DFS. The group of patients who had FISH? patterns for both genes presents a DFS comparable to the group of patients with IHC? patterns for both proteins (p = 0.05, p = 0.05, respectively, Fig. 2a, b) . Finally, the group of patients who had FISH?/IHC? of both genes had a significantly shorter DFS as shown in Fig. 2c , confirmed also in multivariate analysis. The FISH and IHC double positivity phenotype (IGF1R?/EGFR?) were found in about 10 % of the patients studied, and most of these patients were squamous-cell carcinoma. We could speculate that the cases FISH/IHC double positivity with this histological type (although the number is small) should be used to select patients for IGF1R or IGF1R ? EGFR targeted therapy trials.
Furthermore, our results seem to suggest a correlation between high gene copy number and receptor activity, and they confirm the mathematical predictions of model developed by our group [41] .
Interestingly, many of the genes regulated by IGF1R affect ribosome biogenesis and protein translation [3] [4] [5] . Thus, FISH? of IGF1R and EGFR may cooperate in enhanced protein translation, either in a general way or for a specific subset of mRNAs. This finding generates the hypothesis that high gene copy number and overexpression of IGF1R with EGFR cooperatively shifts the repertoire of actively translated mRNAs to a set of genes that drive proliferation and growth, or inhibit apoptosis. Moreover, investigators have suggested that expression levels of IGF1R and EGFR are linked and that the IGF1R/EGFR ratio may serve as a more sensitive prognostic indicator of tumor phenotype and therapeutic response than expression of any single receptor [42, 43] .
Given the possibility of cooperation and shared signaling pathways between the two systems, simultaneously targeting of the EGF and IGF systems may be more effective than targeting either system alone. Small molecule inhibitors and monoclonal antibodies that selectively inhibit either EGFR or IGF1R have to date predominated as effective treatments in co-targeting strategies. The EGFR inhibition may sensitize tumor cells to anti-IGF-IR treatment, particularly in tumors that are strongly driven by EGFR. Prior evidence has indicated that acquired resistance to EGFR inhibition in NSCLC may be associated with enhanced dependency on IGF-IR signaling [44] .
Thus, co-targeting EGFR and IGF-IR could be expected to have additive or synergistic antitumor effects.
In conclusion, in the present study, we have shown that IGF1R and EGFR are frequently FISH? and IHC? in early NSCLC and more frequently present in squamouscell carcinoma. The patients group with IGF1R/EGFR FISH ?/IHC? might represent a subpopulation that is able to develop a more aggressive behavior. Furthermore, our finding could be used as new biomarkers because tumors with IGF1R/EGFR FISH ?/IHC? showed a worse DFS; however, due to limited percentage of this subpopulation and the short follow-up of our study, these results must be interpreted cautiously and need to be confirmed in large prospective trials. escalation study of the anti insulin-like growth factor-I receptor 
